Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Alzheimer's Association | OTHER |
Not provided
Not provided
Not provided
By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.
Alzheimer's disease is a progressive brain disorder that causes memory and thinking problems. Current medications may temporarily help with symptoms but cannot stop the disease from getting worse. As such, new treatments that slow or stop the disease from progressing are needed.
There is some evidence from animal studies that taking creatine monohydrate may improve thinking in Alzheimer's disease and be good for brain health. However, no studies have looked at creatine monohydrate supplementation in humans with Alzheimer's.
Creatine monohydrate is a dietary supplement regulated by the FDA. This is a study that will test if taking creatine monohydrate may be a helpful treatment for people with Alzheimer's disease. In this study, investigators will will evaluate:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Creatine Monohydrate Arm | Experimental | This study a single arm intervention. All participants will receive 20 grams of creatine monohydrate daily for the whole intervention (8 weeks). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Creatine Monohydrate | Dietary Supplement | Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening. |
| Measure | Description | Time Frame |
|---|---|---|
| Adherence to Creatine Monohydrate Intervention | Participants will keep a daily supplement tracker (with the help of a consenting study partner). They will also bring unconsumed creatine monohydrate powder to study visits where study personnel will measure and validate against expected intake. | 8 weeks |
| Change in Blood Creatine | Measure of serum creatine levels at baseline, 4 weeks, and 8 weeks. | Baseline, 4 weeks, and 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Brain Creatine Status | Brain total creatine levels are measured in the brain using magnetic resonance spectroscopy in a 3 T clinical scanner. | Baseline and 8 weeks |
| Change in Cognition |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matthew Taylor, PhD, RD | University of Kansas Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41737290 | Derived | K Taylor M, Smith AN, Choi IY, Lee P, Kelly E, Arora T, Sullivan DK, Burns JM, Swerdlow RH, Wilkins HM. Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease. Alzheimers Dement (N Y). 2026 Feb 22;12(1):e70228. doi: 10.1002/trc2.70228. eCollection 2026 Jan-Mar. | |
| 40977987 | Derived | Smith AN, Sullivan DK, Morris JK, Carbuhn AF, Herda TJ, Taylor MK. Eight weeks of creatine monohydrate supplementation is associated with increased muscle strength and size in Alzheimer's disease: data from a single-arm pilot study. Front Nutr. 2025 Sep 4;12:1670641. doi: 10.3389/fnut.2025.1670641. eCollection 2025. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003401 | Creatine |
| ID | Term |
|---|---|
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D000596 | Amino Acids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
NIH Toolbox (NIH-TB) Cognition Battery will be used to assess changes in a composite global cognition score at baseline and 8 weeks.
| Baseline and 8 weeks |
| Change in Peripheral Mitochondrial Respiration | Blood platelet and leukocyte mitochondrial respiration (oxygen consumption) will be determined using the Oroboros Oxygraph-2K system. | Baseline and 8 weeks |
| Change in Muscle Strength | Muscle strength will be tested on the right quadriceps femoris (upper leg) using an isokinetic dynamometer. | Baseline and 8 weeks |
| Change in Muscle Size | Muscle size of the right quadriceps femoris (upper leg) will be determined using ultrasonography (ultrasound). | Baseline and 8 Weeks |
| 40395689 | Derived | Smith AN, Choi IY, Lee P, Sullivan DK, Burns JM, Swerdlow RH, Kelly E, Taylor MK. Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition. Alzheimers Dement (N Y). 2025 May 19;11(2):e70101. doi: 10.1002/trc2.70101. eCollection 2025 Apr-Jun. |
| 38414003 | Derived | Taylor MK, Burns JM, Choi IY, Herda TJ, Lee P, Smith AN, Sullivan DK, Swerdlow RH, Wilkins HM. Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer's disease. Pilot Feasibility Stud. 2024 Feb 27;10(1):42. doi: 10.1186/s40814-024-01469-5. |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D000602 |
| Amino Acids, Peptides, and Proteins |